Loading
The largest vaccine trial after pancreatic cancer surgery found that algenpantucel-L added nothing to standard chemotherapy.
IMPRESS enrolled 722 patients after resection of pancreatic adenocarcinoma and randomised them to standard adjuvant therapy with or without the whole-cell vaccine algenpantucel-L. Overall survival, the primary endpoint, was not improved, ending the hyperacute vaccine approach in this disease.
Shares Pancreatic cancer: the failed and stopped programmes and why, Off-the-shelf cancer vaccines, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Off-the-shelf cancer vaccines, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Cancer vaccines and oncolytic viruses, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Pancreatic cancer: the failed and stopped programmes and why, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.